Polylactic- Glycolic Acid Microparticles-Encapsulated Prostaglandin E1 as A Novel Strategy In Triple Negative Breast...

Area of Science:

• Biomaterials Science
• Oncology
• Drug Delivery Systems

Background:

• Triple-negative breast cancer (TNBC) presents aggressive characteristics and lacks targeted therapies.
• Prostaglandin E1 (PGE1) exhibits anti-tumor effects but suffers from rapid degradation in vivo.
• Developing stable delivery systems for PGE1 is crucial for effective TNBC treatment.

Purpose of the Study:

• To develop and characterize polylactic-glycolic acid (PLGA) microparticles (MPs) for stabilizing and enabling sustained release of PGE1.
• To evaluate the efficacy and safety of PGE1-loaded MPs for potential TNBC therapy.

Main Methods:

• PGE1-loaded PLGA MPs were fabricated using a double emulsion solvent-evaporation technique.
• Particle characterization included Mastersizer and scanning electron microscopy.
• Encapsulation efficiency, PGE1 release kinetics, and storage stability were assessed via liquid chromatography-mass spectrometry.
• In vitro cytotoxicity was evaluated on TNBC and Caco-2 cells.

Main Results:

• PLGA MPs successfully encapsulated PGE1, demonstrating controlled release profiles.
• PGE1-loaded MPs showed stability across various storage temperatures.
• The carrier exhibited a reliable cytotoxic effect specifically on triple-negative breast cancer cells.
• No significant toxicity was observed in Caco-2 cells, indicating carrier specificity.

Conclusions:

• PLGA microparticles offer a promising strategy for stabilizing PGE1 and facilitating its sustained local delivery.
• This approach holds potential for the intralesional treatment of triple-negative breast cancer post-surgery.
• Further in vivo investigations are warranted to validate the therapeutic efficacy of this delivery system.